Literature DB >> 32481622

Transient Abnormal Myelopoeisis and Mosaic Down Syndrome in a Phenotypically Normal Newborn.

Zachary Prudowsky1,2, HyoJeong Han1,2, Alexandra Stevens1,2.   

Abstract

Transient abnormal myelopoiesis (TAM) is a common and potentially fatal neonatal complication of newborn babies with Down syndrome (DS). Children born with mosaic DS are also at risk of developing TAM. However, due to their variable phenotypes, early identification of patients with mosaic DS may be difficult; thus, early diagnosis of TAM is just as challenging. In this report, we describe a case of a phenotypically normal newborn who presented with concerns for neonatal leukemia. The diagnosis of mosaic DS and TAM was confirmed with abnormal GATA1 mutation testing, highlighting the importance of early GATA1 mutation testing in newborn leukemia with high suspicion for TAM.

Entities:  

Keywords:  GATA1; TAM; acute megakaryocytic leukemia (AMKL); down syndrome; mosaic down syndrome; transient myeloproliferative disease; trisomy 21

Year:  2020        PMID: 32481622     DOI: 10.3390/children7060052

Source DB:  PubMed          Journal:  Children (Basel)        ISSN: 2227-9067


  3 in total

1.  Transient myeloproliferative disorder as the presenting feature for mosaic trisomy 21.

Authors:  Nicole Baca; Pedro A Sanchez-Lara; Rhona Schreck; Celeste C Eno; Fataneh Majlessipour
Journal:  Cold Spring Harb Mol Case Stud       Date:  2021-12-09

2.  Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn.

Authors:  Rahela Aziz-Bose; Franziska Wachter; Roberto Chiarle; Neal I Lindeman; Annette S Kim; Barbara A Degar; Kimberly Davies; Yana Pikman
Journal:  Blood Adv       Date:  2022-05-10

Review 3.  Cytogenetics of Pediatric Acute Myeloid Leukemia: A Review of the Current Knowledge.

Authors:  Julie Quessada; Wendy Cuccuini; Paul Saultier; Marie Loosveld; Christine J Harrison; Marina Lafage-Pochitaloff
Journal:  Genes (Basel)       Date:  2021-06-17       Impact factor: 4.141

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.